Vertex Pharmaceuticals didn’t have to look far to find its next drug program. The Boston biotech company — one of the state’s largest and most profitable — has struck a collaboration with its ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

Vertex’s attempt to treat a rare genetic disease has hit another setback. The biotech tossed two more drug candidates onto the discard pile in response to underwhelming data but, following a playbook ...

When a pharma giant marketing the world’s best-selling drug doubles down on a therapeutic area, a smaller specialist might well feel the pressure. But Vertex doesn't seem to feel that way about AbbVie ...